Entera Bio Ltd (ENTX)
NASDAQ:ENTX
Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$1.20
-$0.11(-4.20%)
At close: 4:00 PM EST
$1.20
-$0.11(-4.20%)
Day’s Range― - ―
52-Week Range$0.91 - $3.22
Previous CloseN/A
Volume29.71K
Average Volume (3M)123.78K
Market Cap
$55.01M
Enterprise Value$49.33M
Total Cash (Recent Filing)$7.11M
Total Debt (Recent Filing)$490.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding46,622,240
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.17K
Enterprise Value/Gross Profit-3.29K
Enterprise Value/Ebitda-4.31
Forecast
1Y Price Target
$10.00Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Oral Peptide Delivery PlatformEntera’s proprietary oral peptide delivery platform targets markets dominated by injectables (osteoporosis, hypoparathyroidism, metabolic disorders). A durable platform advantage could improve patient adherence, broaden addressable markets, and create repeatable product opportunities if clinical efficacy and safety are confirmed.
Regulatory Alignment For Phase 3FDA alignment and a streamlined Phase 3 design under a 505(b)(2) pathway materially reduce trial size, cost, and regulatory uncertainty. A single-tablet registrational plan and a bridge to Forteo data increase the probability of an efficient approval path, shortening time-to-market and conserving development capital.
Partnerships And Experienced LeadershipAppointment of an experienced pharma executive and expansion of the OPKO collaboration strengthen governance, commercialization expertise, and cost-sharing. These structural supports improve clinical oversight, de-risk late-stage development, and enhance strategic execution capacity for commercialization planning.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows indicate ongoing cash burn to fund R&D and trials. This structural cash deficit requires repeated financing, limits runway predictability, and forces management to prioritize funding over long-term optionality until commercial revenues are established.
Reliance On Dilutive FinancingFrequent reliance on equity financings, evidenced by the recent private placement, creates a durable dilution risk for shareholders. Structured warrants and staged financings may cap single investors but still dilute ownership and can pressure future capital raises if clinical timelines slip or costs rise.
Minimal Revenue And Negative MarginsRevenue is small and has contracted sharply, while operating losses remain large. As a clinical-stage biotech without recurring commercial sales, the company lacks sustainable earnings or internal cash generation, meaning long-term viability depends on successful late-stage outcomes or continued external funding.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $3.22 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $55.01M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is May 08, 2026 which is in 21 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Mar 27, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.03.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 46,622,240 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -11.504%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (733.33% Upside)
$10.00 (733.33% Upside)
Insider Transactions
Bought Shares
Worth $121.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
-70.43%
Trailing 12-Months
Asset Growth
70.32%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(733.33% Upside)
Technical Analysis
Ownership Overview
3.25% Insiders
0.05% Mutual Funds
13.86% Other Institutional Investors
82.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---